The short-term efficacy and safety of faricimab in refractory neovascular age-related macular degeneration- the real-world experience in Taiwan

Anti-vascular endothelial growth factor (VEGF) treatment stands as the primary approach for Neovascular Age-Related Macular Degeneration (nAMD). Faricimab has recently emerged as a novel anti-VEGF option for nAMD. This study aims to assess the efficacy of faricimab in patients with refractory nAMD.